Dorrapharma Debuts at CHEMSPEC Europe 2026: Empowering the Global API and CDMO Ecosystem with a Proprietary Innovative R&D Platform

发布时间： 2026-05-08 阅读：16次

分享

On May 6–7, Dorrapharma attended CHEMSPEC Europe 2026 – the premier event for the global fine and specialty chemicals industry – held at Koelnmesse in Cologne, Germany. Centered on its proprietary innovative R&D platform as the core highlight, Dorrapharma presented its API and intermediate product portfolio (powered by core technology platforms) to the European market, alongside the corresponding high-value-added CDMO service capabilities.

【Spotlight on Cutting-Edge, Technology-Driven Strength】

Throughout the exhibition, Dorrapharma’s booth attracted significant attention from new and existing customers across Germany, Switzerland, Italy and Spain. Dorrapharma showcased its core strengths in complex pharmaceutical intermediates, APIs, and integrated CDMO solutions.

In response to global supply chain demands for greater sustainability and cost efficiency, Dorrapharma highlighted its breakthroughs in green process technologies, including continuous flow chemistry, enzymatic catalysis, and asymmetric synthesis. By continuously optimizing synthetic routes, Dorrapharma provided end-to-end lifecycle services – from laboratory R&D to commercial manufacturing – effectively lowering production costs and reducing waste emissions.

【European Hub: Expanding Globalizing Platform Capabilities】

Leveraging its operating center in Switzerland, Dorrapharma has achieved rapid response and localized support to customers in the European market.

At CHEMSPEC Europe 2026, Dorrapharma’s Sino-European team not only presented a mature portfolio of APIs and intermediates, but also secured multiple expressions of interest for CDMO collaborations from several top European pharmaceutical companies, driven by strong confidence in its platform technologies. Drawing on deep understanding of both Chinese and European regulatory frameworks, the team demonstrated that Dorrapharma’s platform could not only “manufacture well” but also “manage exceptionally” – delivering outstanding compliance in critical areas including impurity studies, process scale-up, and regulatory submissions – thereby further enhancing customer trust in the Dorrapharma brand.

【Steady Progress, Building an Innovation-Driven Ecosystem Partner】

As CHEMSPEC Europe 2026 draws to a close, Dorrapharma’s strategic direction is further clarified: with its Nanjing headquarters as the R&D hub and its independent innovation platform as the core engine, Dorrapharma is driving its global business expansion.

Looking ahead, Dorrapharma will continue to strengthen the technological sophistication and digital intelligence capabilities of its R&D platform, expand its pipeline of APIs and intermediates, and enhance the depth and breadth of its CDMO services. Committed to becoming a trusted “innovation-driven API ecosystem partner” for global pharmaceutical companies, Dorrapharma aims to create higher-value products for the global pharmaceutical industry through the spillover effects of its technology platform.